The aim of this study was to investigate the effect of berberine and evodiamine on serotonin transporter (5-HTT) expression and then test how allelic variations previously identified in the promoter region could modulate that effect in the serotonergic neuronal cell line RN46A. Both berberine and evodiamine, alone and in combination, increased 5-HTT mRNA and protein expression significantly across the various alleles. When tested against the S, XS 11 , L G , L A , XL 17 , and XL 18 alleles, respectively, 100 mM berberine increased 5-HTT promoter activities by 67%, 128.7%, 106.9%, 100.4%, 26.2% and 82%, 2 mM evodiamine increased 5-HTT promoter activities by 216.7%, 81.6%, 305.6%, 181.5%, 175.3% and 102.2%. Berberine and evodiamine increased 5-HTT promoter activity differently depending on the genetic variation of the 5-HTTLPR polymorphism. This study has provided a convincing example of how herbal compounds influence the expression of one of the most intensively studied psychiatric candidate genes, the serotonin transporter.
Introduction
The use of herbal medicines is becoming more accepted in the treatment of common diseases such as depression. 1 One step in understanding how herbal medications achieve their affect is to examine functional polymorphisms in candidate genes encoding the transporters known to be of major importance in the mechanism of herbal medicines.
Berberine, a botanical alkaloid isolated from many herbs such as Coptis chinensis and Hydrastis canadensis, has been reported to inhibit weight gain in rodents and reduce food intake in a diet-induced obesity mouse model. [2] [3] [4] Most recently, studies have demonstrated that berberine can have a protective effect against depression and antidepressant-like effects in mice via a mechanism linked to increased levels of serotonin in the hippocampus, frontal cortex and in the brain as a whole. [5] [6] [7] The botanic alkaloid evodiamine has also been shown to inhibit adipocyte differentiation, improve diet-induced obesity and decrease rate of food intake. [8] [9] [10] Although, the mechanistic action of evodiamine in these processes has not yet been fully elucidated, it has been strongly suggested that the pathways involved include the serotonin transporter system. 11 Thus, it is highly possible that the mode of action of both of these compounds could be attributed to the regulation of serotonergic neurotransmission. The serotonin transporter (5-HTT) regulates the serotonin transmission process via the modulation of extracellular fluid serotonin concentrations, which in turn regulates mood, emotion and appetite. 12 The region is also well documented as the pharmacological target of the selective serotonin reuptake inhibitors, which have been for some time the treatment of choice for depression.
Until recently, the serotonin transporter gene-linked polymorphic region (5-HTTLPR), which regulates the transcriptional activity of 5-HTT, was reported to contain three alleles (S, L G and L A ), 13 which have been demonstrated to be associated with varying therapeutic responses during antidepressant treatment.
14,15 Interestingly, our group has recently identified three novel 5-HTTLPR alleles: XS 11 , XL 17 and XL 18 . The functional characterization of these alleles has shown a significant decrease in the expression of the XL 17 allele when compared with the L A allele. In addition, the XS 11 allele displays a similar expression profile as the common 16-repeat S allele. 16 The implications of these finding may be important to scientists utilizing the 'Common Disease Rare Variant' hypothesis 17 to elucidate susceptibility to multifactorial common diseases. Using the 'Common Disease Rare Variant' hypothesis, that multiple rare sequence variations with high penetrance have an important role in the susceptibility to complex diseases, the findings in this study could aid in determining the role serotonin transporter has in emotional-behaviroal disorders.
The serotonergic RN46A cell line derived from rat embryonic raphe nuclei has been used by several research groups to study both the serotonin transporter 18, 19 and its polymorphisms. 16, 20 In this present study, the effect of berberine and/or evodiamine on 5-HTT expression and its promoter activity was investigated with the aim of not only elucidating potential modes of action for berberine and evodiamine on the serotonergic system but also providing an example of the role of pharmacogenetics in herbal medicine.
Materials and methods

Cell culture and drug treatments
The immortalized rat raphe-derived neuronal cell line RN46A was graciously provided by Dr Scott R Whittemore (School of Medicine, University of Louisville). Cells were cultured in Dulbecco's modified Eagle's medium (SigmaAldrich, Saint Louis, MO, USA) with 10% Fetal Bovine Serum (Atlanta Biologicals, Lawrenceville, GA, USA), 100 U ml À1 penicillin, 100 mg ml À1 streptomycin and 250 mg ml À1 geneticin (Sigma-Aldrich) at 33 1C in a humidified 5% CO 2 atmosphere for 2 days, and then the medium was changed to Dulbecco's modified Eagle's medium with 10% fetal bovine serum for another 2 days. Varying concentrations of berberine and/or evodiamine (Sigma-Aldrich) were then added for 24 h and the cells were used for MTT (thiazolyl blue tetrazolium bromide) assays, RNA and protein extraction, or dual-luciferase reporter assays as described below.
MTT assay MTT assays were used to determine the effect of either berberine or evodiamine, alone or in combination, on the viability of RN46A cells and has been described previously. 8 Briefly, RN46A cells were plated in 96-well culture plates at a density of 4 Â 10 3 cells per well and cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum, supplemented with varying concentrations of berberine and evodiamine, alone and in combination. Medium was removed after incubation for 24 h and MTT (0.5 mg ml À1 , 50 ml per well) was added. The plates were incubated at 37 1C for 4 h, followed by the addition of dimethyl sulfoxide (150 ml per well) and incubated at 37 1C for 1 h. Optical density was measured at 570 nm, with 650 nm as background.
Real-time reverse transcriptase PCR Real-time reverse transcriptase PCR analysis was used to measure mRNA expression of 5-HTT using b-actin as an internal control. Briefly, total RNA was isolated from RN46A cells using Trizol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. RNA was quantified using absorption of light at 260 and 280 nm, and sample integrity was checked by electrophoresis on a 1.5% agarose gel. Total RNA (0.8 mg) from each sample was used in a reverse transcription reaction using the TaqMan Reverse Transcription Reagents (Applied Biosystems, Foster City, CA, USA) following the manufacturers' instructions. PCR was carried out using SYBR green Master Mix (Applied Biosystems) using the following primer (Integrated DNA Technologies, Coralville, IA, USA) sequences, 5-HTT forward primer: 
Immunoblot analysis
Protein expression of 5-HTT was analyzed via western blot. Total proteins were isolated from RN46A cells following treatment with the natural compounds or vehicle. Briefly, cells were washed twice with phosphate-buffered saline and then lysed in a buffer containing HEPES-Tx-PI buffer: 910 mM HEPES, 5 mM EDTA, 350 mM sucrose, 1 mg ml À1 leupeptin, 1 mg ml À1 pepstatin, 1% Triton-X, 1 mM phenylmethanesulfonylfluoride, processed with a 25G needle and centrifuged at 11 000 r.p.m. for 5 min.
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Protein concentration was determined using the Micro BCA Protein Assay Kit (Fisher Scientific, Pittsburgh, PA, USA) according to the manufacturers instructions. Proteins (25 mg) were loaded and separated by electrophoresis using the BioRad Electrophoretic System (Bio-Rad Laboratories, Hercules, CA, USA) (60 V for 1 h followed by 90 V for 5 h). The proteins were then transferred to nitrocellulose membranes at 35 V overnight. The membrane was then blocked for 1 h at room temperature in 5% non-fat milk in Trisbuffered saline, then washed with Tween-20-Tris-buffered saline (0.1% Tween-20) three times (15 min, 5 min and 5 min), followed by incubation with primary monoclonal antibodies; 5-HTT (dilution 1:300) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and b-actin (dilution 1:1000; Sigma-Aldrich) at room temperature for 2 h. The membrane was then rinsed three times in Tween-20-Tris-buffered saline for 15 min, 5 min, 5 min, and incubated at room temperature for 1 h with horseradish peroxidase-conjugated second antibody (1:5000). The membrane was incubated in ECL reagent (GE Healthcare, Piscataway, NJ, USA) for 1 min. Proteins bands were visualized using the UVP image analysis system (UVP, Upland, CA, USA).
Plasmid construction DNA samples were obtained from human subjects from the Vermont Family Study and were graciously provided by Dr James J Hudziak. Primer sequences (Integrated DNA Technologies) used to amplify the 5-HTTLPR alleles for sequencing and creation of reporter constructs were described previously 20 and are as follows: forward primer: 5 0 -G GCGTTGCCGCTCTGAATGC-3 0 and reverse primer: 5 0 -GAG GGACTGAGCTGGACAACCAC-3 0 . The PCR products of the six 5-HTTLPR alleles were subcloned into the TOPO TA cloning vector PCR2.1-TOPO (Invitrogen) and transformed into One Shot TOP10 competent Escherichia coli cells according to the manufacturer's instructions. The 5-HTTLPR alleles were subsequently sequenced in both directions using the M13 forward and M13 reverse primers specific to the pCR2.1-TOPO vector using Big-Dye Terminator v3.1 Cycle Sequencing Kit according to the manufacturer's instructions (Applied Biosystems).
Dual-luciferase reporter assay
Following sequence verification, constructs containing the six 5-HTTLPR alleles (S, XS 11 , L G , L A , XL 17 , and XL 18 alleles) were individually subcloned from pCR2.1-TOPO vectors into the luciferase reporter vector pGL4.10 (firefly luciferase, Promega, Madison, WI, USA) using standard molecular techniques. The co-transfection of the 5-HTTLPR pGL4.10 constructs and the pRL-SV40 vector (Promega) into RN46A cells was carried out using Lipofectamine 2000 (Invitrogen) and was described previously. 20 In all, 100 mM berberine or 2 mM evodiamine (treatment group) or control was added at the beginning of the transfection. Expression was measured 24 h following transfection using the Dual-Luciferase Reporter Assay System (Promega). Relative light units for both the firefly and Renilla luciferase were measured using a 20/20 n Luminometer (Turner Biosystems, Sunnyvale, CA, USA), and the ratio between the firefly relative light unit and Renilla relative light unit in each sample was determined. The final value was the relative expression (relative light unit ratio) of treatment group to the control group.
Statistical analysis
The data was analyzed by the analysis of variance procedure of Statistical Analysis System (SAS Institute, 1999-2001, Cary, NC, USA). Significant differences between groups were determined using Student's t-test or Duncan's multiple range tests at the Po0.05 (*).
Results
Neither berberine nor evodiamine when used alone or in combination significantly inhibits the viability of RN46A cells MTT assays showed that concentrations of either berberine alone (10 and 100 mM), evodiamine alone (2 and 4 mM) or in combination (100 mM berberine and 2 mM evodiamine) did not have a significant effect on cell viability. However, 100 mM berberine combined with 4 mM evodiamine did inhibit cell viability significantly ( Figure 1 ).
Berberine, evodiamine and their combination increase expression of 5-HTT mRNA in RN46A cells Reverse transcriptase PCR analysis showed that berberine alone (10, 100 mM), evodiamine alone (2, 4 mM) and berberine (100 mM) combined with evodiamine (2 mM) increased 5-HTT mRNA expression by 0.3±0.3-, 2.9±1.1-, 1.5±0.7-, 0.7 ± 0.3-and 4.4 ± 1-fold, respectively, when compared with controls ( Figure 2 ). Statistically significant increases in 5-HTT mRNA expression were noted with 100 mM berberine, 2 mM evodiamine, 4 mM evodiamine and 100 mM berberine in combination with 2 mM evodiamine.
5-HTT protein expression is also increased in RN46A cells following treatment with berberine, evodiamine, and their combination 5-HTT protein expression profiles in RN46A cells following treatment with berberine and evodiamine were consistent with the observed mRNA expression profile. In all, 100 mM berberine, 2 mM evodiamine and 100 mM berberine combined (Figure 3) .
The levels of 5-HTT gene expression modulated by berberine, evodiamine and their combination are associated with polymorphisms in the 5-HTT-linked polymorphic region When compared with controls (vehicle-treated groups), treatment of 100 mM berberine for 24 h increased 5-HTT promoter activities by 67 ± 19%, 128.7 ± 14.1%, 106.9 ± 27.3%, 100.4±17.1%, 26.2±14.2% and 82±15.7% for the S allele, XS 11 allele, L G allele, L A allele, XL 17 allele and XL 18 allele, respectively. Thus, berberine enhanced 5-HTT promoter activity differently depending on the 5-HTTLPR polymorphism in RN46A cells (Figure 4a ).
In addition, treatment of 2 mM evodiamine for 24 h increased 5-HTT promoter activities by 216.7±13.9%, 81.6 ± 10.3%, 305.6 ± 24.2%, 181.5 ± 14.2%, 175.3 ± 13.7% and 102.2 ± 8.3% for the S allele, XS 11 allele, L G allele, L A allele, XL 17 allele and XL 18 allele, respectively, when compared with controls (vehicle-treated groups). As observed with berberine, evodiamine-enhanced 5-HTT promoter activity is dependent on the 5-HTTLPR polymorphism in RN46A cells as well (Figure 4b ).
As the treatment of 100 mM berberine combined with 2 mM evodiamine increased both mRNA and protein expression of 5-HTT more than treatment of 100 mM berberine or 2 mM evodiamine alone, we tested the effects of this combination on promoter activity for the S allele compared with berberine or evodiamine alone. Treatments of 100 mM berberine, 2 mM evodiamine and their combination for 24 h significantly increased 5-HTT promoter activities of the S allele by 62.8±5.2%, 250.5±22.1% and 315.3±10.7%, respectively, when compared with controls.
Conclusion and Discussion
The use of herbal medicines is becoming increasingly popular for the treatment of common diseases. Our previous studies have shown that the herbal compounds berberine and evodiamine have potential as antiobesity agents. Other groups have also demonstrated an antidepressive effect of berberine. [5] [6] [7] [8] 21, 22 The consideration of how depression and obesity are related at the biological and behavioral levels have led many to look at the role of serotonin in both of these diseases. The serotonin transporter (5-HTT) regulates serotonin transmission, which in turn modulates mood, emotion and appetite. 12 The 5-HTT is also well documented as the pharmacological target of selective serotonin reuptake inhibitors, and its expression has been reported to be downregulated by the antidepressants fluoxetine and sertraline. 23, 24 As a result, we aimed to study the expression of 5-HTT when exposed to the herbal compounds berberine and evodiamine.
In this report, we used MTT assays to demonstrate that berberine and evodiamine have minimal toxic effects on the serotonergic cell line RN46A. Using real-time reverse transcriptase PCR to measure the expression of 5-HTT in RN46A neuronal cells, we have demonstrated for the first time that berberine and evodiamine can increase 5-HTT mRNA levels (Figure 2 ). A berberine concentration of 100 mM significantly increased 5-HTT expression by 2.9-fold (P ¼ 0.031) and treatment with 2 and 4 mM evodiamine significantly increased 5-HTT expression by 0.7-fold (P ¼ 0.048) and 1.5-fold (P ¼ 0.034), respectively, when compared with control. These results strongly suggest berberine and evodiamine are important regulators of serotonin transmission. More interestingly, treatment of 100 mM berberine combined with 2 mM evodiamine significantly increased 5-HTT mRNA expression by 4.4-fold (P ¼ 0.013) when compared with control, which suggests that possible additive/synergistic effects exist when berberine and evodiamine are combined and that such a combination could be a novel addition to known clinical medications used to treat depression or inhibit food intake.
We also hypothesized that 5-HTT protein expression could also be directly affected, and our experiments revealed that treatment with either 100 mM berberine or 2 mM evodiamine, alone and in combination, increased 5-HTT protein expression by 0.6-fold (P ¼ 0.081), 0.9-fold (P ¼ 0.03) and 1.2-fold (P ¼ 0.02), respectively, when compared with control. However, the levels of increased protein expression were not proportional to levels of increased mRNA expression of 5-HTT and are probably reflective of post-transcriptional modifications and/or regulation. Nevertheless, treatment with both compounds did increase 5-HTT protein expression, which in turn would enhance serotonin reuptake and as a result lower the level of serotonin in the synaptic cleft. A similar mechanism is seen when selective serotonin reuptake enhancers such as tianeptine are used as antidepressants. 25, 26 The serotonin transporter-linked polymorphic region (5-HTTLPR) is a functional polymorphism present in the promoter region of the serotonin transporter gene and is a variable number of tandem repeats consisting of varying 20-23 bp imperfect repeat sequences. Interestingly, the 5-HTTLPR polymorphism has been shown to regulate pharmacological responses, including modulation of the behavioral response to methylphenidate in attention deficit hyperactivity disorder children, the analgesic response to the short acting opioid remifentanil and the efficacy of antidepressants in women. [27] [28] [29] As berberine and evodiamine increased 5-HTT expression, we then investigated whether the levels of increased 5-HTT expression were allele specific. We examined gene expression using the wellknown 5-HTTLPR alleles (14 repeats: short allele; 16 repeats: long allele; and L G /L A : single-nucleotide polymorphism A4G (rs25531)) and our three recently identified novel alleles (11 repeats: XS; 17 repeats: XL 17 ; and 18 repeats: XL 18 ) in response to berberine and evodiamine using reporter constructs. Treatment of 100 mM berberine increased the 5-HTT promoter activity (Figure 4a ) in all six alleles. However, although 100 mM berberine treatment did result in allele-specific-enhanced 5-HTT promoter activity, there was no significant difference among the XS 11 , L G , L A and XL 18 alleles. On the other hand, 5-HTT promoter activity was increased significantly less in the XL 17 allele when compared with the XS 11 , L G , L A or XL 18 alleles. These results suggest that higher doses of berberine would potentially be required for the treatment of depression in an individual with the XL 17 allele.
In addition, treatment of 2 mM evodiamine resulted in allele-specific differential 5-HTT promoter activity as well. Of particular interest is that 2 mM evodiamine treatment had a significantly different effect on the activity of the 5-HTT L G (305.6%) and L A alleles (181.5%). Thus, although there is only one nucleotide difference between the L G and L A (single-nucleotide polymorphism A4G) alleles, promoter response to evodiamine was altered, which demonstrates a possible example of pharmacogenetics in herbal medicine. The L G allele is known to introduce an AP2 transcription factor at this site. 20 It is possible that evodiamine may inhibit the effects of AP2 on transcriptional repression and we aim to investigate that possibility in future work.
As we had observed that 100 mM berberine plus 2 mM evodiamine upregulated 5-HTT mRNA and protein expression to a greater extent than berberine or evodiamine treatment alone, we subsequently investigated whether the combinatorial treatment would also enhance promoter activity. The results did show that for the S allele, treatment with 100 mM berberine combined with 2 mM evodiamine did increase promoter activity (315.3%) more than treatment of 100 mM berberine (62.8%) or 2 mM evodiamine (250.5%).
Therefore, the combination of berberine with evodiamine could have more potential as an antidepressant or foodintake inhibitor than berberine or evodiamine alone. It is well known that the S allele of 5-HTTLPR results in attenuated transcription of SERT. 16, 20, 30 It is also hypothesized that this decrease in 5-HTT expression is a potential risk factor for major depression when combined with adverse life events. 31 Evodiamine and berberine treatment therefore may provide a protective effect for depression in individuals with a low expressing 5-HTT allele by increasing receptor concentration in serotonergic neurons. These findings could lead to a more thorough understanding of the roles of herbal medicine in the treatment of depression and/or obesity.
Pharmacogenetics, the study of the effect of an individual genetic variation on drug response, is a major focus area of individualized medicine. A number of pharmacogenetic studies have been reported in herbal medicine; however, they have focused mainly on the drug-metabolism enzymes and not to our knowledge on the serotonin system. 32, 33 A major significant finding in this study is that the level of berberine and evodiamine-enhanced gene expression is associated with variation in the 5-HTT-linked polymorphic region.
